CRF2 Agonist for the Treatment of Worsening Heart Failure

PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

August 7, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Worsening Heart Failure
Interventions
DRUG

COR-1167

28-day treatment

DRUG

Placebo

28-day treatment

Trial Locations (10)

73135

NOT_YET_RECRUITING

South Oklahoma Heart Research, LLC, Oklahoma City

0102

RECRUITING

Aleksandre Aladashvili Clinic LLC, Tbilisi

0112

RECRUITING

"LTD Israeli-Georgian Medical Research Clinic Healthycore", Tbilisi

0159

NOT_YET_RECRUITING

Acad. G. Chapidze Emergency Cardiology Center LTD, Department of Internal Medicine and Medical Research, Tbilisi

RECRUITING

Acad. G.Chapidze Emergency Cardiology Center, LTD, Department of Multi-center Clinical Trials, Tbilisi

NOT_YET_RECRUITING

Bokhua Memorial Cardiovascular Center LTD, Tbilisi

NOT_YET_RECRUITING

St. Michael's Hospital LLC, Tbilisi

NOT_YET_RECRUITING

Tbilisi Heart and Vascular Clinic, LTD, Tbilisi

0167

RECRUITING

Georgian Dutch Hospital, Tbilisi

0186

NOT_YET_RECRUITING

LTD Tbilisi Heart Center, Tbilisi

Sponsors
All Listed Sponsors
collaborator

Worldwide Clinical Trials

OTHER

lead

Corteria Pharmaceuticals

INDUSTRY

NCT06815471 - CRF2 Agonist for the Treatment of Worsening Heart Failure | Biotech Hunter | Biotech Hunter